Founded in 2002 and based in Strasbourg, France, NovAliX is a drug discovery-focused CRO supporting the drug discovery process from screening to optimized leads. With around 230 researchers, NovAliX provides strong capabilities in medicinal chemistry combined with screening platforms such as FBDD, covalent fragment screening and DEL. Experts offer in vitro pharmacology services and a unique biophysical and structural platform encompassing MS, SPR, NMR, MST, DSF, HDX, X-ray crystallography & cryo-EM — including membrane proteins. NovAliX also offers support in synthetic chemistry and chemical process research including a flow chemistry platform. CONTACT info@novalix.com
Location: France, Grand Est, Strasbourg
Employees: 201-500
Total raised: $2.4M
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | Capital Gr... | capitalgra... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.12.2020 | - | $2.4M | - |
Mentions in press and media 3
| Date | Title | Description |
| 01.04.2025 | Aqemia's $7.4 Million Grant: A Leap into RNA Drug Discovery | Aqemia, a biotech company, is on the brink of a breakthrough. With a fresh $7.4 million grant from the France 2030 initiative, it aims to revolutionize drug discovery. This funding is not just a financial boost; it’s a ticket to uncharted t... |
| 01.04.2025 | Aqemia: $7.4 Million Grant Secured To Advance Epitranscriptomics Programs | Aqemia announced it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Creating on successes in epitranscriptomics, Aqemia looks to develop novel small-molecule drugs aga... |
| 08.08.2024 | NovAliX Receives Investment from Bruker | NovAliX, a Strasbourg, France-based preclinical contract research organization (CRO) specializing in expert drug discovery services, received an investment from Bruker (Nasdaq: BRKR). The amount oof the deal was not disclosed. The company i... |